SEC Form 4 · accession 0001209191-17-002689
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Tarriff
Officer — CEO · Director
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $84.92 | Jan 4, 2017 | A | 200,900 | A | — | Jan 3, 2027 | Common Stock | 200,900 | 200,900 | D |
Explanation of responses
- F1The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 4, 2018, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.